Federal regulators have granted clearance to a new diagnostic tool designed to assist healthcare professionals in identifying autism spectrum disorder in children, marking another step forward in the integration of biometric technology into pediatric care.
The Food and Drug Administration cleared the tool, known as Neurora, to inform clinical decisions regarding children ranging from 18 months to 12 years of age. Developed by Argus Cognitive, Inc., the system relies on an analysis of more than 100 distinct biometrics to help assess whether a pediatric patient meets the criteria for an autism diagnosis.
The clearance comes at a time when the medical community is actively seeking more efficient and objective ways to navigate the diagnostic process. According to estimates from the Centers for Disease Control and Prevention, autism currently affects approximately 1 in 31 children. Despite this high prevalence, many families face extensive wait times to secure a comprehensive evaluation for their child. Federal public health data indicates that the median age of diagnosis hovers at just under 4 years old, a timeline that clinicians and advocates have long sought to shorten to ensure children can access early intervention services during critical developmental windows.
Under the operational framework for Neurora, clinicians can upload standard video and audio recordings captured during routine behavioral assessments directly into a secure digital portal. The automated software then evaluates a wide array of non-verbal and verbal cues, meticulously measuring facial expressions, voice modulation patterns, eye gaze behavior, and other subtle indicators. By processing these data points, the tool evaluates how a specific child’s behavioral responses compare against normative data gathered from both autistic and neurotypical children.
Developers emphasize that the software is not intended to serve as a standalone diagnostic instrument. Rather, the generated data is meant to be considered in conjunction with other clinical findings and professional judgment.
"We built Neurora to support clinicians evaluating children for autism," said Dr. Attila Meretei, CEO and co-founder of Argus Cognitive. "Neurora works inside the assessment clinicians already use, without protocol changes or proprietary hardware, and is fully automated. Our goal is to reinforce every diagnosis with robust, quantitative evidence."
The journey from conception to market clearance for Neurora involved rigorous scientific research and external backing. Argus Cognitive noted that the development of the tool was supported by a specialized National Institutes of Health grant aimed at fostering entrepreneurial medical technologies. Furthermore, the clinical validity of the system was documented in a study published earlier this year in the journal Frontiers in Psychiatry. That research demonstrated that the biometric tool successfully distinguished between children with and without autism in nearly 78 percent of evaluated cases, providing the empirical foundation necessary to pursue regulatory review.
With this latest green light, Neurora joins a small, growing class of FDA-cleared technological aids available to pediatric diagnosticians, psychologists, and developmental pediatricians. Over the past several years, federal regulators have cleared a handful of other pioneering devices intended to streamline or supplement the diagnostic workflow.
Among these is the EarliPoint Evaluation for ASD, which utilizes specialized eye-tracking technology to monitor and analyze a child’s visual engagement and social attention behaviors during structured testing. Another precedent is Canvas Dx, an algorithm-driven platform that analyzes comprehensive information submitted by parents and healthcare providers alongside video footage of the child to assist practitioners in making informed diagnostic decisions.
While these technological advancements offer new pathways to support clinical evaluations, medical professionals continue to stress the irreplaceable value of comprehensive, multidisciplinary human evaluations. The integration of AI-driven biometrics, eye-tracking systems, and algorithmic analysis tools is intended to alleviate the immense strain on specialized diagnostic centers, reduce frustrating backlog waitlists for families, and provide practitioners with objective, quantitative layers of evidence to reinforce their clinical observations. As these tools gradually find their way into clinical practices nationwide, the broader medical and advocacy communities remain focused on ensuring equitable access to early screening, timely diagnoses, and the essential support services that follow.
